Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2011

Lee Young Joo, Yoon Kyong-Ah, Han Ji-Youn, Kim Heung Tae, Yun Tak, Lee Geon Kook, Kim Hyae Young, Lee Jin Soo

Abstract excerpt

PURPOSE: Circulating cell-free DNA (CFDNA) was investigated as potential screening or prognostic markers in a variety of cancers. This study investigated its clinical significance in a homogeneous group of lung cancer patients. EXPERIMENTAL DESIGN: We analyzed the blood samples of 134 never smokers with advanced lung adenocarcinoma, who were enrolled in a prospective randomized phase III study (First-SIGNAL)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cell-Free System

Share to Gefitinib

Share to Genes, erbB-1

Share to Quinazolines

Share to Smoking

Source

Identifiers

PMID: 21653691
DOI: 10.1158/1078-0432.CCR-11-0400

Genes

ACTB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.PMID 21653691Read ↗

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Semantic proximity Read ↗

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line ChemotherapySemantic proximity Read ↗

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.Semantic proximity Read ↗

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.Semantic proximity Read ↗

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.Semantic proximity Read ↗

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancerSemantic proximity Read ↗

Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.Semantic proximity Read ↗

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLCSemantic proximity Read ↗

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.Semantic proximity Read ↗

Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patientsSemantic proximity Read ↗

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.